查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1807516

核醫市場按產品類型、給藥方式、用途、應用和最終用戶分類－2025-2030 年全球預測

Nuclear Medicine Market by Product Type, Mode Of Administration, Usage, Application, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計核醫市場規模在 2024 年將達到 146 億美元，在 2025 年將成長至 160.5 億美元，在 2030 年將達到 270.4 億美元，複合年成長率為 10.80%。

主要市場統計數據
基準年2024年 146億美元
預計2025年 160.5億美元
預計2030年 270.4億美元
複合年成長率（%） 10.80%

探索不斷發展的核子醫學領域：深入了解推動全球醫療保健進步的最新診斷和治療創新

核子醫學已成為現代醫療保健的基石，利用放射性同位素的獨特特性實現精準診斷和標靶治療。從早期的伽馬攝影機成像到如今先進的診療方法，該領域不斷發展，以應對日益成長的個人化醫療需求、分子生物學的進步以及成像硬體和放射性藥物化學的持續創新。價值鏈上的相關人員——放射性藥物開發商、設備製造商、臨床醫生和監管機構——都在應對不斷變化的臨床指南、不斷擴展的適應症以及日益嚴格的安全和供應審查所帶來的挑戰。

確定影響核子醫學的變革性變化，從傳統的同位素方案到多種模式的突破性放射性藥物發展

在放射性藥物研發的突破和整合技術創新的推動下，核醫領域正經歷一場變革性的轉變。近年來，針對特定生物標記物客製化的新型分子示蹤劑的激增，使臨床醫生能夠以前所未有的靈敏度檢測病理過程。同時，數位影像檢測器和先進的斷層掃描重建演算法提高了影像解析度和量化能力。這兩種趨勢正朝著無縫整合正子斷層掃描 (PET)、單光子發射電腦斷層掃描 (SEP) 和電腦斷層掃描 (CT) 的混合平台發展，從而促進對疾病的更全面觀察。

評估 2025 年美國關稅對核醫供應鏈、研究合作動態與跨國放射性藥物貿易流量的累積影響

2025年美國關稅的實施為核醫供應鏈帶來了新的複雜性，影響了同位素材料和影像設備的進口。隨著關鍵原料和專用零件關稅的生效，製造商面臨生產成本上升和物流限制的壓力。這項變更促使一些製造商重新思考籌資策略，投資國內同位素生產設施，並尋求垂直整合，以減輕進口關稅的影響。

透過深入了解產品類型、管理模式、用途、應用和最終用戶概況等關鍵市場細分，明確您的策略

市場區隔洞察揭示了一個支援策略規劃和資源配置的多層面框架。依產品類型，市場分為診斷性放射性藥物（正子斷層掃描同位素和單光子發射電腦斷層掃描同位素）和治療性核子醫學（包括近距離放射治療同位素，例如銫-131、碘-125、銥-192和鈀-103，以及使用α和BETA發射核素的放射性藥物治療）。這種分層分類有利於針對臨床效用、製造複雜性和監管途徑進行有針對性的分析。

分析美洲、歐洲、中東和非洲以及亞太市場的區域動態和優先促進因素，以確定核醫擴大策略

核子醫學的區域動態反映了美洲、歐洲、中東和非洲以及亞太地區不同的投資模式、基礎設施成熟度和法規環境。在美洲，北美成熟的醫療保健體係正在推動先進影像平台和尖端放射性追蹤劑的廣泛應用，而南美市場則專注於擴展基礎 PET 和 SPECT 功能，以滿足日益成長的診斷需求。該地區的相關人員正在平衡對經濟高效的供應解決方案的需求和對最新診療通訊協定的需求。

介紹推動核醫價值鏈創新、卓越營運和競爭優勢的關鍵產業相關人員和策略夥伴關係

主要企業正在建立策略聯盟，以加速產品線開發並擴大其市場佔有率。一家全球診斷影像設備製造商正與放射性藥物開發商合作，共同開發端到端解決方案，以最佳化新型示蹤劑的掃描器效能。特種同位素製造商正與受託製造廠商合作，以擴大針對性α和BETA發送器的生產；核醫藥局正透過與醫院和診斷中心授權合約來擴大其地理覆蓋範圍。

可操作的建議，使產業領導者能夠最佳化核醫學生態系統的供應鏈、法規遵循和投資重點

為了因應地緣政治和貿易中斷，產業領導者應優先考慮透過投資區域產能和簽訂聯盟供應協議來實現同位素採購的多元化。透過積極參與標準機構加強監管參與，有助於協調主要市場的核准流程，並縮短新化合物的臨床應用時間。此外，將先進的數據分析技術融入採購和庫存管理，可提高預測準確性，並最大限度地減少短壽命同位素的浪費。

了解核子醫學市場情報中用於確保資料完整性、全面的市場分析和可靠檢驗的嚴格調查方法

本報告中的見解基於嚴謹的調查方法，該方法結合了一級研究和二級研究、數據三角測量和專家檢驗。對同行評審出版物、專利申請和監管資料庫的廣泛審查提供了基礎知識。我們也對放射性藥物製造商、診斷影像設備供應商、學術研究中心和監管機構的高階主管進行了深入訪談，以獲得有關新興趨勢和產業挑戰的第一手觀點。

摘要關鍵發現和策略意義，幫助相關人員利用新興趨勢，塑造核子醫學領域的未來

先進示踪劑的研發、數位成像技術的突破以及不斷演變的法律規範的融合，正在將核醫學重塑為一個真正精準驅動的領域。從2025年關稅對供應鏈韌性的影響，到對不同產品類型和應用領域細分市場的洞察，本分析凸顯了策略適應性和協作創新的重要性。區域動態進一步凸顯了採取量身定做的方法以解決區域基礎設施、監管協調和市場成熟度問題的需求。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 擴展氟-18放射性示蹤劑用於腫瘤靶向PET成像
  • 整合人工智慧和機器學習，實現 PET/CT 影像分析自動化，提升診斷準確性
  • 開發將診斷影像同位素（如鎵-68）與治療同位素（如鎦-177）結合的診療對，用於個人化癌症治療
  • 由於全身影像靈敏度提高且輻射劑量減少，全身 PET影像檢查儀的採用率不斷提高
  • 迴旋加速器和放射性藥物基礎設施的進步，以支持本地生產短壽命放射性核種並減少供應鏈限制
  • 新型α發射放射性核種療法的監管發展和核准，例如基於錒-225的前列腺癌治療方法。
  • 雲端基礎的數位平台的實施，用於多中心研究中核子醫學攝影數據的安全共用和協作
  • 開發經濟高效的緊湊型迴旋加速器，以分散 PET 示踪劑的生產並擴大其在社區醫院的覆蓋範圍
  • 針對 PSMA 和 HER2 的新興放射免疫結合物，可精準應用於轉移性疾病
  • 應用深度學習演算法最佳化放射性藥物合成通訊協定並提高產量一致性

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章：2025年美國關稅的累積影響

第8章 核子醫學市場（依產品類型）

  • 診斷放射性藥物
    • 正子斷層掃描（PET）同位素
    • 單光子發射電腦斷層掃描 (SPECT) 同位素
  • 治療性核子醫學
    • 近距離放射治療近距離放射治療
      • 銫-131
      • 碘-125
      • 銥192
      • 鈀-103
    • 放射性藥物治療
      • α發射體
      • BETA射線發射器

9. 依管理方法分類的核子醫學市場

  • 靜脈注射
  • 口服

第 10 章 核子醫學市場：依用途

  • 診斷程序
    • PET掃描儀
      • 模擬PET
      • 數字PET
    • SPECT 掃描儀
  • 治療程序

第 11 章核醫市場：按應用

  • 心臟病
  • 內分泌
  • 胃腸病學
  • 神經
  • 瘤
  • 整形外科
  • 呼吸系統醫療設備

第 12 章 核子醫學市場（依最終使用者）

  • 學術研究機構
  • 診斷中心
  • 醫院
    • 公立醫院
    • 私立醫院

第 13 章：美洲核子醫學市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第14章歐洲、中東和非洲的核子醫學市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

第15章：亞太核子醫學市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • FPNV定位矩陣2024
  • 競爭分析
    • 3B Pharmaceuticals GmbH
    • Actinium Pharmaceuticals, Inc.
    • BJ Madan & Co.
    • Bayer AG
    • Bracco SpA
    • BWX Technologies, Inc.
    • Clarity Pharmaceuticals
    • Curium
    • Eli Lilly and Company
    • GE HealthCare
    • IBA
    • Institute of Isotopes Co., Ltd
    • Isotopia Molecular Imaging Ltd.
    • Jubilant Pharma Limited
    • Lantheus Holdings, Inc.
    • Medi-Radiopharma Co., Ltd.
    • Nordion
    • Northstar Medical Technologies LLC
    • Novartis AG
    • Nusano, Inc.
    • PeptiDream Inc.
    • Radiopharm Theranostics Limited
    • SHINE Technologies, LLC
    • Siemens Healthineers AG
    • Sinotau Pharmaceuticals Group
    • South African Nuclear Energy Corporation
    • State Atomic Energy Corporation Rosatom
    • Thor Medical AS by Nordic Nanovector ASA

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-A339DAEFAF4C

The Nuclear Medicine Market was valued at USD 14.60 billion in 2024 and is projected to grow to USD 16.05 billion in 2025, with a CAGR of 10.80%, reaching USD 27.04 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 14.60 billion
Estimated Year [2025] USD 16.05 billion
Forecast Year [2030] USD 27.04 billion
CAGR (%) 10.80%

Navigating the Evolving Nuclear Medicine Landscape: Foundational Insights Into Modern Diagnostics and Therapeutic Innovations Driving Global Healthcare Progress

Nuclear medicine has emerged as a cornerstone of modern healthcare, harnessing the unique properties of radioisotopes to enable both precise diagnostics and targeted therapies. From early gamma camera imaging to today's sophisticated theranostic approaches, the field has evolved in response to rising demand for personalized care, advances in molecular biology, and relentless innovation in imaging hardware and radiopharmaceutical chemistry. Stakeholders across the value chain-including radiopharmaceutical developers, equipment manufacturers, clinical practitioners, and regulators-are navigating a landscape shaped by shifting clinical guidelines, expanding indications, and heightened scrutiny of safety and supply security.

Against this backdrop, the convergence of digital imaging technologies, novel tracer development, and integrated data analytics is catalyzing a new era of nuclear medicine. Technological strides such as high-resolution detectors, digital positron emission tomography, and hybrid imaging platforms are amplifying diagnostic accuracy, while breakthroughs in targeted alpha and beta emitters are unlocking therapeutic options for oncology, cardiology, and neurology. This introduction lays the foundation for an in-depth exploration of the forces reshaping nuclear medicine, setting the stage for a detailed examination of market drivers, segmentation insights, regional dynamics, and strategic imperatives that will define the industry's trajectory through 2025 and beyond.

Identifying Transformational Shifts Reshaping Nuclear Medicine From Traditional Isotope Protocols to Breakthrough Radiopharmaceutical Developments Across Multiple Modalities

The nuclear medicine landscape is undergoing transformative shifts, originating from breakthroughs in radiopharmaceutical discovery and convergent technological innovations. Recent years have witnessed a surge in novel molecular tracers tailored to specific biomarkers, enabling clinicians to detect pathological processes with unprecedented sensitivity. Concurrently, digital imaging detectors and advanced tomographic reconstruction algorithms have elevated image resolution and quantification capabilities. These dual trends are converging in hybrid platforms that seamlessly integrate positron emission tomography, single photon emission computed tomography, and computed tomography, fostering a more holistic view of disease.

Beyond hardware and tracer advances, the industry is responding to evolving regulatory frameworks that emphasize safety, standardization, and harmonized licensing across jurisdictions. Governments and international bodies are working to streamline radiopharmaceutical approval pathways and improve cross-border supply arrangements, while also enforcing stringent quality controls for isotope production and handling. This regulatory momentum, combined with growing collaboration between academic research institutes and contract manufacturing organizations, is accelerating the translation of preclinical candidates into clinical-grade products. As a result, the sector is poised for a new wave of innovation, where precision diagnostics and targeted therapies coalesce to deliver more effective and efficient patient care.

Assessing the Cumulative Impact of 2025 United States Tariffs on Nuclear Medicine Supply Chains, Research Collaboration Dynamics, and Cross-Border Radiopharmaceutical Trade Flows

The introduction of United States tariffs in 2025 has injected fresh complexity into nuclear medicine supply chains, affecting both isotopic materials and imaging equipment imports. As tariffs on critical raw materials and specialized components took effect, manufacturers faced upward pressure on production costs and logistical constraints. This shift has prompted some producers to reconsider sourcing strategies, invest in domestic isotope generation facilities, and pursue vertical integration to mitigate exposure to import levies.

In tandem, collaborative research networks that once relied on seamless transnational exchange of isotopes and consumables are adjusting to new financial and regulatory burdens. Academic and clinical partners in Europe and Asia are exploring local production partnerships to ensure uninterrupted access to critical radiotracers. Meanwhile, equipment providers have intensified after-sales service and spare-parts stocking in regional hubs to circumvent tariff-driven delays. These adjustments underscore a broader rethinking of the global nuclear medicine ecosystem, where supply resilience and cost containment have become as vital as clinical efficacy for sustaining growth and innovation.

Uncovering Key Market Segmentation Insights Across Product Types, Administration Modes, Usage Categories, Clinical Applications, and End User Profiles for Strategic Clarity

Insights into market segmentation reveal a multifaceted framework that underpins strategic planning and resource allocation. Across product types, the field is delineated into diagnostic radiopharmaceuticals-encompassing positron emission tomography isotopes and single photon emission computed tomography isotopes-and therapeutic nuclear medicine, which includes brachytherapy isotopes such as cesium-131, iodine-125, iridium-192 and palladium-103, alongside radiopharmaceutical therapies employing both alpha emitters and beta emitters. This layered breakdown enables targeted analysis of clinical utility, manufacturing complexity, and regulatory pathways.

The mode of administration distinguishes between intravenous injection and oral ingestion, reflecting divergent pharmacokinetic profiles and patient convenience considerations. Usage patterns are classified into diagnostic procedures and therapeutic procedures, with diagnostic workflows segmented by PET scanner modalities-ranging from analog to digital systems-and SPECT scanners designed for high-resolution imaging. Clinical application categories span cardiology, endocrinology, gastroenterology, neurology, oncology, orthopedics and pulmonology, each driving unique demand trajectories based on disease prevalence and standard-of-care protocols. Finally, end users include academic and research institutes, specialized diagnostic centers, and hospitals-which themselves are segmented into government and private facilities-highlighting the varying operational requirements and procurement processes across the healthcare spectrum.

Analyzing Regional Dynamics and Priority Drivers in the Americas, Europe Middle East Africa, and Asia Pacific Markets for Informed Decisions in Nuclear Medicine Expansion Strategies

Regional dynamics in nuclear medicine reflect divergent investment patterns, infrastructure maturity, and regulatory environments across the Americas, Europe Middle East Africa and Asia Pacific. In the Americas, established healthcare systems in North America drive high adoption of advanced imaging platforms and cutting-edge radiotracers, while Latin American markets focus on expanding basic PET and SPECT capacity to address growing diagnostic needs. Stakeholders in this region are balancing the need for cost-effective supply solutions with demand for the latest theranostic protocols.

Europe Middle East Africa presents a mosaic of adoption rates, with Western Europe leading in standardized regulatory frameworks and collaborative research consortia. Emerging markets in the Middle East and Africa are at earlier stages of establishing isotope generation and distribution networks, often leveraging public-private partnerships to accelerate capability building. Regulatory harmonization efforts are underway to reduce complexity for multinational clinical trials and cross-border collaborations.

Asia Pacific's nuclear medicine sector is characterized by rapid capacity expansion in countries such as China, Japan and India, driven by government initiatives to enhance domestic isotope production and bolster nuclear medicine infrastructure. This region is also a hotbed for technological innovation, with local manufacturers investing heavily in digital imaging detectors and mobile cyclotron installations. As a result, Asia Pacific is emerging as both a consumer and producer of advanced radiopharmaceutical solutions.

Profiling Leading Industry Stakeholders and Strategic Partnerships Fueling Innovation, Operational Excellence, and Competitive Advantage in the Nuclear Medicine Value Chain

Leading companies are forging strategic alliances to accelerate pipeline development and reinforce market presence. Global imaging equipment manufacturers have partnered with radiopharmaceutical developers to co-develop end-to-end solutions that optimize scanner performance for novel tracers. Specialized isotope producers are collaborating with contract development and manufacturing organizations to scale up production of targeted alpha and beta emitters, while nuclear pharmacies are expanding their geographic footprint through licensing agreements with hospitals and diagnostic centers.

In parallel, a new generation of agile start-ups is leveraging proprietary radiochemistry platforms to engineer next-generation theranostic agents, often in joint ventures with academic research institutions. These collaborations are fostering a robust innovation ecosystem, where intellectual property is shared under structured agreements to de-risk development and accelerate regulatory submissions. Equally, established pharmaceutical companies are investing in nuclear medicine capabilities through acquisitions, signaling growing recognition of radiopharmaceuticals as a core component of precision medicine portfolios.

Delivering Actionable Recommendations to Empower Industry Leaders in Optimizing Supply Chains, Regulatory Compliance, and Investment Priorities Within Nuclear Medicine Ecosystems

Industry leaders should prioritize diversification of isotope sourcing by investing in regional production capacity and forming consortium-based supply agreements to hedge against geopolitical and trade disruptions. Strengthening regulatory engagement through active participation in standards-setting bodies will help align approval processes across key markets and reduce time-to-clinic for novel compounds. Moreover, integrating advanced data analytics into procurement and inventory management can enhance forecasting accuracy and minimize waste for short-lived isotopes.

Organizations must also consider forging cross-sector alliances with digital health and artificial intelligence specialists to develop companion diagnostic platforms that personalize treatment pathways. Deploying modular cyclotron technologies in strategic locations will not only improve supply resilience but also drive down logistics costs. Finally, dedicating resources to workforce training and safety protocols will ensure that facilities maintain high compliance standards, safeguard staff and patients, and support sustainable growth in an increasingly complex environment.

Detailing Rigorous Research Methodology Employed to Ensure Data Integrity, Comprehensive Market Analysis, and Robust Validation in Nuclear Medicine Market Intelligence

This report's insights are grounded in a rigorous methodology that combines primary and secondary research, data triangulation and expert validation. An extensive review of peer-reviewed publications, patent filings and regulatory databases provided the foundational knowledge base. Detailed interviews were conducted with senior executives across radiopharmaceutical manufacturers, imaging equipment providers, academic research centers and regulatory authorities to capture firsthand perspectives on emerging trends and industry challenges.

Quantitative data sets covering production volumes, technology adoption rates and demographic trends were analyzed using statistical techniques to identify underlying patterns and correlations. Segmentation analysis was applied across product types, administration modes, clinical applications and end-user categories to ensure that findings are granular and actionable. The resulting conclusions were subjected to multiple rounds of expert review to verify accuracy and relevance, ensuring that the final report delivers robust, evidence-based insights for strategic decision making.

Summarizing Critical Findings and Strategic Implications for Stakeholders to Capitalize on Emerging Trends and Navigate the Future of the Nuclear Medicine Sector

The convergence of advanced tracer development, digital imaging breakthroughs and evolving regulatory frameworks is reshaping nuclear medicine into a truly precision-driven discipline. From the impact of 2025 tariffs on supply chain resilience to the nuanced segmentation insights across product types and clinical applications, this analysis underscores the importance of strategic adaptability and collaborative innovation. Regional dynamics further highlight the need for tailored approaches that address local infrastructure, regulatory alignment and market maturity.

Looking ahead, stakeholders who proactively invest in supply diversification, regulatory harmonization and cross-sector partnerships will be best positioned to capture the next wave of opportunities in theranostics and diagnostic imaging. By leveraging the comprehensive findings outlined in this report, decision-makers can refine their go-to-market strategies, optimize resource allocation and accelerate time-to-clinic for transformative nuclear medicine solutions. This confluence of innovation, regulation and strategic foresight will define the sector's trajectory and its impact on patient care in the coming decade.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Expansion of fluorine-18 based radiotracers for targeted PET imaging in oncology
  • 5.2. Integration of artificial intelligence and machine learning for automated PET/CT image analysis and diagnostic accuracy
  • 5.3. Growth of theranostic pairs combining diagnostic imaging isotopes like gallium-68 with therapeutic isotopes like lutetium-177 for personalized cancer treatment
  • 5.4. Increasing adoption of total-body PET scanners to improve sensitivity and reduce radiation dose in whole-body imaging studies
  • 5.5. Advancements in cyclotron and radiopharmacy infrastructure to support local production of short-lived radionuclides and reduce supply chain constraints
  • 5.6. Regulatory progress and approvals for novel alpha-emitting radionuclide therapies such as actinium-225 based treatments for prostate cancer
  • 5.7. Implementation of cloud-based digital platforms for secure sharing and collaboration of nuclear imaging data across multi-center trials
  • 5.8. Development of cost-effective compact cyclotrons to decentralize production of PET tracers and expand access in community hospitals
  • 5.9. Emergence of novel radioimmunoconjugates targeting PSMA and HER2 for precision nuclear medicine applications in metastatic disease
  • 5.10. Application of deep learning algorithms to optimize radiopharmaceutical synthesis protocols and enhance yield consistency

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Nuclear Medicine Market, by Product Type

  • 8.1. Introduction
  • 8.2. Diagnostic Radiopharmaceuticals
    • 8.2.1. Positron Emission Tomography (PET) Isotopes
    • 8.2.2. Single Photon Emission Computed Tomography (SPECT) Isotopes
  • 8.3. Therapeutic Nuclear Medicine
    • 8.3.1. Brachytherapy Isotopes
      • 8.3.1.1. Cesium-131
      • 8.3.1.2. Iodine-125
      • 8.3.1.3. Iridium-192
      • 8.3.1.4. Palladium-103
    • 8.3.2. Radiopharmaceutical Therapy
      • 8.3.2.1. Alpha Emitters
      • 8.3.2.2. Beta Emitters

9. Nuclear Medicine Market, by Mode Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous Injection
  • 9.3. Oral Ingestion

10. Nuclear Medicine Market, by Usage

  • 10.1. Introduction
  • 10.2. Diagnostic Procedure
    • 10.2.1. PET Scanners
      • 10.2.1.1. Analog PET
      • 10.2.1.2. Digital PET
    • 10.2.2. SPECT Scanners
  • 10.3. Therapeutic Procedure

11. Nuclear Medicine Market, by Application

  • 11.1. Introduction
  • 11.2. Cardiology
  • 11.3. Endocrinology
  • 11.4. Gastroenterology
  • 11.5. Neurology
  • 11.6. Oncology
  • 11.7. Orthopedics
  • 11.8. Pulmonology

12. Nuclear Medicine Market, by End Users

  • 12.1. Introduction
  • 12.2. Academic & Research Institutes
  • 12.3. Diagnostic Centers
  • 12.4. Hospitals
    • 12.4.1. Government Hospitals
    • 12.4.2. Private Hospitals

13. Americas Nuclear Medicine Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Nuclear Medicine Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Nuclear Medicine Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. 3B Pharmaceuticals GmbH
    • 16.3.2. Actinium Pharmaceuticals, Inc.
    • 16.3.3. B J Madan & Co.
    • 16.3.4. Bayer AG
    • 16.3.5. Bracco S.p.A.
    • 16.3.6. BWX Technologies, Inc.
    • 16.3.7. Clarity Pharmaceuticals
    • 16.3.8. Curium
    • 16.3.9. Eli Lilly and Company
    • 16.3.10. GE HealthCare
    • 16.3.11. IBA
    • 16.3.12. Institute of Isotopes Co., Ltd
    • 16.3.13. Isotopia Molecular Imaging Ltd.
    • 16.3.14. Jubilant Pharma Limited
    • 16.3.15. Lantheus Holdings, Inc.
    • 16.3.16. Medi-Radiopharma Co., Ltd.
    • 16.3.17. Nordion
    • 16.3.18. Northstar Medical Technologies LLC
    • 16.3.19. Novartis AG
    • 16.3.20. Nusano, Inc.
    • 16.3.21. PeptiDream Inc.
    • 16.3.22. Radiopharm Theranostics Limited
    • 16.3.23. SHINE Technologies, LLC
    • 16.3.24. Siemens Healthineers AG
    • 16.3.25. Sinotau Pharmaceuticals Group
    • 16.3.26. South African Nuclear Energy Corporation
    • 16.3.27. State Atomic Energy Corporation Rosatom
    • 16.3.28. Thor Medical AS by Nordic Nanovector ASA

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. NUCLEAR MEDICINE MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. NUCLEAR MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. NUCLEAR MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. NUCLEAR MEDICINE MARKET: RESEARCHAI
  • FIGURE 26. NUCLEAR MEDICINE MARKET: RESEARCHSTATISTICS
  • FIGURE 27. NUCLEAR MEDICINE MARKET: RESEARCHCONTACTS
  • FIGURE 28. NUCLEAR MEDICINE MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. NUCLEAR MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CESIUM-131, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CESIUM-131, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IODINE-125, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IODINE-125, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IRIDIUM-192, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IRIDIUM-192, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PALLADIUM-103, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PALLADIUM-103, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORAL INGESTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORAL INGESTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ANALOG PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ANALOG PET, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIGITAL PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIGITAL PET, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT SCANNERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PROCEDURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PROCEDURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PULMONOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 137. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 138. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 151. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 152. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 153. CANADA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 154. CANADA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 155. CANADA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 156. CANADA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 157. CANADA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 158. CANADA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 159. CANADA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 160. CANADA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 161. CANADA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 162. CANADA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 163. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 164. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 165. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 166. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 167. CANADA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. CANADA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 169. CANADA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 170. CANADA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 171. CANADA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 172. CANADA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 173. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 175. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 176. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 177. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 178. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 179. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 180. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 181. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 182. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 183. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 185. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 186. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 187. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 188. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 189. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 190. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 191. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 193. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 195. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 196. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 197. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 200. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 201. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 202. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 203. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 204. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 205. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 207. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 209. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 210. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 211. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 212. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 213. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 214. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 215. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 216. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 217. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 218. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 219. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 220. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 221. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 223. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 224. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 225. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 226. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 227. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 228. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 229. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 230. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 231. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 233. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 234. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 235. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 236. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 237. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 238. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 239. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 241. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 242. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 243. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 244. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 271. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 278. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 291. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 295. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 298. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 299. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 300. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 301. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 302. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 303. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 304. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 305. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 307. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2024 (USD MILLION)
  • TABLE 308. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025-2030 (USD MILLION)
  • TABLE 309. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 310. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 311. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 312. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2025-2030 (USD MILLION)
  • TABLE 313. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 315. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 316. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 317. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 318. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 319. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 321. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 322. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 323. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 324. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 325. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2024 (USD MILLION)
  • TABLE 326. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2025-2030 (USD MILLION)
  • TABLE 327. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 328. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 329. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 330. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 331. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY US